HIBERCELL

HiberCell was launched in 2019 with investor support from ARCH Venture Partners and other leading life science investors. With our focus on targeting stress-driven vulnerabilities, we have developed a portfolio of therapeutic candidates with the potential to improve the lives of cancer patients... Our team is led by proven biotech executives who believe combining traditional drug development methods with computational expertise will enable efficient clinical development of our first-in-human therapeutic candidates. Our team embodies the values of scientific rigor and urgency, which are important to our mission of developing therapeutics that improve the lives of patients... Developing therapies targeting adaptive-stress driven vulnerabilities to combat treatment resistance, cancer relapse, and metastasis.

Also known as: Hibercell Inc

Primary location: New York United States